Bluejay Diagnostics Enters Material Agreement, Discloses Details in SEC Filing
Bluejay Diagnostics Inc. reported entry into a material definitive agreement on June 2, 2026. The move triggers standard SEC disclosure obligations and sets contractual performance and potential milestone deadlines for the microcap diagnostics company.
dailyhodl.comBluejay Diagnostics Inc. (BJDX) filed a Form 8-K with the SEC on June 2, 2026, stating it had entered into a material definitive agreement, the company disclosed in Item 1.01.
The filing covers the Marlborough, Massachusetts-based developer of near-patient diagnostic tests for critical-care settings. Bluejay's lead product candidate is the Symphony IL-6 test, designed to provide rapid results from a finger-stick blood sample at the point of care.
Item 1.01 states that the company entered into the agreement but does not name the counterparty or disclose the contract type or dollar value in the summary data. Item 9.01 exhibits the agreement or related documents. The filing also includes Item 7.01 Regulation FD disclosure, indicating the company furnished information to the public under fair-disclosure rules, and Item 9.01 for exhibits and financial statements.
Operationally the company moves from a state without this binding contract to one governed by its terms. The agreement takes effect immediately upon execution on or before the June 2 filing date. No termination under Item 1.02 is reported.
Downstream the company must meet any performance milestones or payment schedules specified in the contract. Failure to do so could trigger default, termination rights or financial penalties under standard commercial terms. The filing itself satisfies the SEC's four-business-day reporting deadline for material definitive agreements.
Any material amendments or future events tied to the contract will require additional Form 8-K filings. If the agreement involves equity issuance, debt or a partnership that meets Regulation FD thresholds, Bluejay must ensure ongoing compliance with disclosure controls.
This marks the latest contractual disclosure by the company since it began trading as a public microcap following its 2021 SPAC merger. Bluejay has previously reported supply, licensing and financing arrangements typical for development-stage diagnostics firms seeking commercialization partners or capital.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Related Stories
thehindu.comU.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
prnewswire.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
insidermonkey.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…